🎈 Up Big Today: Find today's biggest gainers (some over 50%!) with our free screenerTry Stock Screener

AstraZeneca, Gilead merger doubted by Wall Street analysts

Published 08/06/2020, 08:08
Updated 08/06/2020, 18:30
© Reuters. FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York
UK100
-
GILD
-
AZN
-

By Manas Mishra

(Reuters) - A merger between AstraZeneca (L:AZN) and Gilead Sciences Inc (O:GILD) is unlikely due to significant political hurdles, Wall Street analysts said on Monday after a Bloomberg report that the British drugmaker last month had contacted its U.S. rival about a deal.

Gilead's shares were up marginally in morning trading, paring their earlier gains after CNBC reported, citing sources, that the companies were not in active talks.

Such a merger would unite two drugmakers at the forefront of efforts to fight the new coronavirus, but could be politically sensitive as governments seek control over potential vaccines or treatments.

Gilead, whose drug remdesivir has shown improvement in COVID-19 patients in clinical trials and has been cleared for emergency use in several countries, was not interested in combining with another big drugmaker, Bloomberg reported on Sunday.

"We would be very surprised if ownership of Gilead was permitted to leave the United States," said SVB Leerink analyst Geoffrey Porges.

"Domestic R&D and manufacturing capabilities, particularly in healthcare, have never been more important to the national interest."

Citi analyst Andrew Baum said he anticipated that the U.S. administration would likely seek to block potential acquisitions of any major U.S. biopharma company involved in the development of future therapeutics for the pandemic.

Gilead shares were up 0.6% in mid-day trading after gaining more than 3% earlier in the session.

© Reuters. FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York

AstraZeneca's shares closed down 2.7% on the FTSE 100 as investors contemplated a large payout and questioned the rationale of a deal that would create a company with a combined market value of about $232 billion, based on Friday's closing prices.

"We have to admit that even the willingness to consider such a perplexing, and in our view, potentially value-destroying deal sets our nerves on edge," said Guggenheim analyst Seamus Fernandez.

AstraZeneca is developing a vaccine for COVID-19 through its partnership with Oxford University.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.